TY - JOUR T1 - The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00694-2018 VL - 52 IS - 5 SP - 1800694 AU - Richard Beasley AU - Grace Bird AU - James Harper AU - Mark Weatherall Y1 - 2018/11/01 UR - http://erj.ersjournals.com/content/52/5/1800694.abstract N2 - Should short-acting β-agonist (SABA) reliever monotherapy be replaced by combination inhaled corticosteroid (ICS)/fast-onset β-agonist as reliever therapy in asthma patients at Global Initiative for Asthma step 1 [1]? This uncertainty is the latest chapter in the controversy relating to the risks and benefits of β-agonist therapy in asthma management [2]. This 70-year controversy began with the introduction of isoprenaline and the concerns that it caused severe refractory asthma and an increased risk of death [3–5].A paradigm shift in asthma management that addresses the paradoxes of SABA reliever therapy is required; consideration needs to be given to replacement of SABA reliever with ICS/fast-onset β-agonist reliever therapy across the range of asthma severity http://ow.ly/ccff30lNLPv ER -